The article discusses the global landscape of COVID-19 vaccine development, highlighting the rapid progress made since the genetic sequence of SARS-CoV-2 was published in January 2020. The Coalition for Epidemic Preparedness Innovations (CEPI) is working with global health authorities and vaccine developers to support the development of vaccines against COVID-19. CEPI has developed a database to track the global vaccine development activity, including projects reported through the WHO and other sources. As of April 2020, there were 115 vaccine candidates, with 78 confirmed active and 37 unconfirmed. Most candidates aim to induce neutralizing antibodies against the S protein of the virus. The development landscape includes various technology platforms, such as nucleic acid, viral vector, recombinant protein, and inactivated virus approaches. Many of these platforms are not currently used in licensed vaccines, but experience in other fields is encouraging developers to explore next-generation approaches for increased speed and efficiency. The article also notes the diversity of vaccine developers, with 72% of confirmed active candidates being developed by private/industry entities. Most development activity is in North America, with significant efforts also in China and Europe. The article emphasizes the need for international coordination to ensure equitable access to vaccines, particularly in low-resource regions. CEPI has called for funding to support global vaccine development efforts, focusing on speed, manufacturing, and global access. The article concludes that the global vaccine R&D effort is unprecedented in scale and speed, with the potential for vaccines to be available under emergency use protocols by early 2021. The development of vaccines for COVID-19 involves new virus targets, novel vaccine technology platforms, and innovative development paradigms, which may increase the risks associated with delivering a licensed vaccine. The article also highlights the need for strong international coordination and cooperation between vaccine developers, regulators, policymakers, funders, public health bodies, and governments to ensure that promising late-stage vaccine candidates can be manufactured in sufficient quantities and equitably supplied to all affected areas.The article discusses the global landscape of COVID-19 vaccine development, highlighting the rapid progress made since the genetic sequence of SARS-CoV-2 was published in January 2020. The Coalition for Epidemic Preparedness Innovations (CEPI) is working with global health authorities and vaccine developers to support the development of vaccines against COVID-19. CEPI has developed a database to track the global vaccine development activity, including projects reported through the WHO and other sources. As of April 2020, there were 115 vaccine candidates, with 78 confirmed active and 37 unconfirmed. Most candidates aim to induce neutralizing antibodies against the S protein of the virus. The development landscape includes various technology platforms, such as nucleic acid, viral vector, recombinant protein, and inactivated virus approaches. Many of these platforms are not currently used in licensed vaccines, but experience in other fields is encouraging developers to explore next-generation approaches for increased speed and efficiency. The article also notes the diversity of vaccine developers, with 72% of confirmed active candidates being developed by private/industry entities. Most development activity is in North America, with significant efforts also in China and Europe. The article emphasizes the need for international coordination to ensure equitable access to vaccines, particularly in low-resource regions. CEPI has called for funding to support global vaccine development efforts, focusing on speed, manufacturing, and global access. The article concludes that the global vaccine R&D effort is unprecedented in scale and speed, with the potential for vaccines to be available under emergency use protocols by early 2021. The development of vaccines for COVID-19 involves new virus targets, novel vaccine technology platforms, and innovative development paradigms, which may increase the risks associated with delivering a licensed vaccine. The article also highlights the need for strong international coordination and cooperation between vaccine developers, regulators, policymakers, funders, public health bodies, and governments to ensure that promising late-stage vaccine candidates can be manufactured in sufficient quantities and equitably supplied to all affected areas.